Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Brivaracetam→

Brivaracetam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
357336-20-0
Molecular formula
C11H20N2O2
Molecular weight
212.29 g/mol
Drug class
Antiseizure medicine (ASM)high-affinity synaptic vesicle protein 2A (SV2A) ligand
Mechanism of action
The precise mechanism by which brivaracetam exerts its anticonvulsant effect is not known. It binds with high and selective affinity to synaptic vesicle protein 2A (SV2A) in the brain; this binding may contribute to its antiseizure activity and should not be presented as a fully established causal mechanism.
Indications / reported uses
  • Treatment of partial-onset (focal) seizures in patients aged 1 month and older; may be used as monotherapy or adjunctive therapy according to the specific product label and jurisdiction

Sources: US DailyMed — Brivaracetam label, updated October 7 2026 · NLM DailyMed — Brivaracetam prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Brivaracetam Environmental Risk Assessment (ERA) (the Brivaracetam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.